Page 1 of 1 Form PTO-1449 U.S. Department of Commerce Atty Docket No. (REV. 2-82) Patent and Trademark Office (071838.0142 10/699 035 Applicants SUPPLEMENTAL INFORMATION Bateman et al. DISCLOSURE STATEMENT Filing Date Group Art Unit BY APPLICANT October 31, 2003 1644 (Use several sheets if necessary) U.S. PATENT DOCUMENTS Document No. Dete Class Subclass Filing Date Neme **IfAppropriate** FOREIGN PATENT DOCUMENT Translator Ves No. Document No SubClass OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.) Arikawa-Hirasawa et al., "Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perfecan gene. Nat. Genet. 2001 Apr;27(4):431-4. Arikawa-Hirasawa et al., "Perlecan is essential for cartilage and cephalic development," Nat Genet. 1999 Nov:23(3):354-8.

Examiner

Date Considered Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Atty. Docket No. 077375.0151 Serial No. 11/411,973 Express Mail No. ED 762 053 957 US PATENT

 Applicants:
 Bateman et al.
 Conf. No.:
 3842

 Serial No.:
 10/699,035
 Examiner:
 Haddad, M.M.

 Filed:
 October 31, 2003
 Group Art Unit:
 1644

For: A MOLECULAR MARKER

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

November 2, 2006

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants being to the attention of the Examiner the documents listed on the attached PTO-1449 and respectfully requests that the listed documents be considered by the Examiner and made of record in the abovecaptioned application.

This Supplemental Information Disclosure Statement is being filed together with a Supplemental Response to a March 31, 2006 Office Action. Copies of the listed documents are attached as Exhibits 1-2 that accompany the Supplemental Response.

This Statement is being filed after the mailing date of the first action on the merits but before the date of any final action, and is accompanied by authorization in the Fee Transmittal, to charge the fee of \$180 pursuant to \$7 C.F.R. § 1.17(p) to a deposit account. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by initializing the PTO-1449 form and returning a copy of the initialized form with the next office communication.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior

NY02:565853.1

-1-

Atty. Docket No. 077375.0151 Serial No. 11/411,973 Express Mail No. ED 762 053 957 US PATENT

art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants do not believe that any additional fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Director is hereby authorized, in the accompanying Transmittal and Fee Transmittal to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377.

Respectfully submitted,

Kimberley A Gavin, Reg. No. 51,723
Agent for Applicants

Baker Botts L.L.P
Customer No. 21003
30 Rockefeller Plaza

New York, NY 10012-4498 212-408-2500